Cansino Biotech (06185): The mRNA platform is one of the technical platforms for the company's layout with abnormal fluctuations in A-share trading

Zhitong Finance App News, Cansino Biotech (06185) issued an announcement. The daily closing price increase deviation value of the company's A-share shares accumulated over 30% for 3 consecutive trading days on August 19, August 20, and August 21, 2026, which is an abnormal fluctuation in stock trading.

According to the company's own inspection, the company's current production and operation activities are normal, and the internal business order is normal. The company's market environment and industry policies have not undergone major adjustments.

As of the disclosure date of this announcement, the controlling shareholder and actual controller of the company confirmed that, as of the disclosure date of this announcement, the controlling shareholders and actual controllers of the company had no important matters that should be disclosed but not disclosed, including but not limited to major matters such as planning mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestment, and asset injection.

The company is concerned about recent developments in mRNA technology on the market. The mRNA platform is one of the technology platforms in the company's layout. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In the field of treatment, the company is promoting research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as in vivo CAR related therapies, which are currently in the early stages.

As of the disclosure date of this announcement, the company has found no media reports or market rumors that may have a significant impact on the company's stock trading price and require clarification or response from the company.

After verification, the company did not find any other major events that could have had a significant impact on the company's stock price. The company's directors, senior management, controlling shareholders, and their co-actors did not trade the company's shares during the abnormal fluctuation of the company's current stock trading.